Ocera Therapeutics Company Profile (NASDAQ:OCRX)

About Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCRX
  • CUSIP: N/A
  • Web: www.ocerainc.com
Capitalization:
  • Market Cap: $29.96 million
  • Outstanding Shares: 26,510,000
Average Prices:
  • 50 Day Moving Avg: $1.23
  • 200 Day Moving Avg: $1.52
  • 52 Week Range: $0.52 - $3.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $575,999.00
  • Price / Sales: 52.01
  • Book Value: $0.52 per share
  • Price / Book: 2.17
Profitability:
  • EBIDTA: ($25,000,000.00)
  • Net Margins: -23,816.53%
  • Return on Equity: -116.62%
  • Return on Assets: -73.71%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 4.57%
  • Quick Ratio: 4.57%
Misc:
  • Average Volume: 2.30 million shs.
  • Beta: 2.17
  • Short Ratio: 1.11
 

Frequently Asked Questions for Ocera Therapeutics (NASDAQ:OCRX)

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."

How were Ocera Therapeutics' earnings last quarter?

Ocera Therapeutics Inc (NASDAQ:OCRX) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.04. Ocera Therapeutics had a negative net margin of 23,816.53% and a negative return on equity of 116.62%. View Ocera Therapeutics' Earnings History.

Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2017?

5 equities research analysts have issued 1-year price targets for Ocera Therapeutics' stock. Their predictions range from $1.00 to $10.00. On average, they expect Ocera Therapeutics' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Ocera Therapeutics.

Are investors shorting Ocera Therapeutics?

Ocera Therapeutics saw a drop in short interest in the month of April. As of April 28th, there was short interest totalling 1,377,634 shares, a drop of 14.5% from the April 13th total of 1,610,740 shares. Based on an average daily volume of 877,414 shares, the days-to-cover ratio is presently 1.6 days.

Who are some of Ocera Therapeutics' key competitors?

Who are Ocera Therapeutics' key executives?

Ocera Therapeutics' management team includes the folowing people:

  • Linda S. Grais M.D. J.D., President, Chief Executive Officer, Director
  • Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Stan Bukofzer M.D., Chief Medical Officer
  • Steven P. James, Lead Independent Director
  • Willard H. Dere M.D., Director
  • Nina S. Kjellson, Independent Director
  • Michael F. Powell Ph.D., Independent Director
  • Anne M. VanLent, Independent Director

Who owns Ocera Therapeutics stock?

Ocera Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.11%), VHCP Management II LLC (5.16%), Vanguard Group Inc. (4.58%), Hikari Power Ltd (1.06%) and Endurant Capital Management LP (0.65%). Company insiders that own Ocera Therapeutics stock include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Stan Bukofzer and Wendall Wierenga. View Institutional Ownership Trends for Ocera Therapeutics.

Who sold Ocera Therapeutics stock? Who is selling Ocera Therapeutics stock?

Ocera Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Endurant Capital Management LP. View Insider Buying and Selling for Ocera Therapeutics.

Who bought Ocera Therapeutics stock? Who is buying Ocera Therapeutics stock?

Ocera Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Vanguard Group Inc. and Hikari Power Ltd. Company insiders that have bought Ocera Therapeutics stock in the last two years include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Stan Bukofzer and Wendall Wierenga. View Insider Buying and Selling for Ocera Therapeutics.

How do I buy Ocera Therapeutics stock?

Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocera Therapeutics' stock price today?

One share of Ocera Therapeutics stock can currently be purchased for approximately $1.13.


MarketBeat Community Rating for Ocera Therapeutics (NASDAQ OCRX)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $4.50 (298.23% upside)

Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017AegisReiterated RatingBuy$3.00LowView Rating Details
5/10/2017HC WainwrightReiterated RatingBuy$4.00HighView Rating Details
1/31/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
1/30/2017Stifel NicolausDowngradeBuy -> Hold$1.00N/AView Rating Details
10/24/2016Brean CapitalSet Price TargetBuy$10.00N/AView Rating Details
3/6/2016Cowen and CompanyReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:OCRX)
Earnings by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Earnings History by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.24)($0.28)ViewListenView Earnings Details
4/29/2016Q1($0.33)($0.36)$0.03 millionViewN/AView Earnings Details
3/3/2016Q415($0.33)($0.34)$0.02 millionViewN/AView Earnings Details
8/3/2015Q215($0.40)($0.46)$0.04 millionViewN/AView Earnings Details
4/30/2015Q115($0.29)($0.34)$0.03 millionViewN/AView Earnings Details
3/11/2015Q414($0.46)($0.28)$0.03 millionViewN/AView Earnings Details
11/13/2014Q314($0.50)($0.34)$0.23 millionViewN/AView Earnings Details
8/11/2014Q114($0.45)($0.46)$0.03 millionViewN/AView Earnings Details
5/8/2014($0.43)($0.27)$0.05 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details
11/13/2013Q3 13($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)
Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocera Therapeutics (NASDAQ:OCRX)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 35.00%
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Institutional Ownership by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Michael ByrnesCFOBuy3,000$1.28$3,840.00View SEC Filing  
12/7/2016Linda S GraisInsiderBuy7,000$2.14$14,980.00View SEC Filing  
10/13/2016Stan BukofzerInsiderBuy2,500$2.64$6,600.00View SEC Filing  
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.00View SEC Filing  
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.00View SEC Filing  
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.00View SEC Filing  
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.00View SEC Filing  
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ocera Therapeutics (NASDAQ:OCRX)
Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
Source:
DateHeadline
nasdaq.com logoOcera Therapeutics to Host KOL Conference Call on Hepatic ... - Nasdaq
www.nasdaq.com - May 26 at 7:58 PM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Rating Reiterated by Aegis
www.americanbankingnews.com - May 24 at 9:38 AM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 22 at 8:18 AM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Short Interest Update
www.americanbankingnews.com - May 18 at 9:24 PM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 18 at 9:02 PM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 14 at 4:34 PM
seekingalpha.com logoOcera Therapeutics' (OCRX) CEO Linda Grais on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 8:17 AM
streetinsider.com logoOcera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance
www.streetinsider.com - May 12 at 12:30 AM
finance.yahoo.com logoEdited Transcript of OCRX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 7:28 PM
americanbankingnews.com logoZacks: Analysts Anticipate Ocera Therapeutics Inc (OCRX) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 11 at 6:28 PM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 10 at 6:40 PM
finance.yahoo.com logoInvestor Network: Ocera Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 6:35 PM
finance.yahoo.com logoOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - May 9 at 6:35 PM
finance.yahoo.com logoOcera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
finance.yahoo.com - May 3 at 8:03 PM
finance.yahoo.com logoETFs with exposure to Ocera Therapeutics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 8:03 PM
americanbankingnews.com logoOcera Therapeutics (OCRX) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 2:14 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Likely to Impact Ocera Therapeutics (OCRX) Share Price
www.americanbankingnews.com - April 30 at 4:10 PM
americanbankingnews.com logoOcera Therapeutics (OCRX) Receiving Somewhat Critical Media Coverage, Study Shows
www.americanbankingnews.com - April 24 at 6:26 PM
americanbankingnews.com logo Brokerages Expect Ocera Therapeutics Inc (OCRX) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - April 20 at 10:18 PM
finance.yahoo.com logoETFs with exposure to Ocera Therapeutics, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 7:00 PM
americanbankingnews.com logoOcera Therapeutics (OCRX) Given Media Sentiment Score of 0.28
www.americanbankingnews.com - April 19 at 12:59 PM
americanbankingnews.com logoOcera Therapeutics' (OCRX) "Buy" Rating Reaffirmed at Aegis
www.americanbankingnews.com - April 17 at 10:32 AM
americanbankingnews.com logoOcera Therapeutics (OCRX) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 16 at 2:35 PM
americanbankingnews.com logoShort Interest in Ocera Therapeutics Inc (OCRX) Declines By 32.1%
www.americanbankingnews.com - April 16 at 7:08 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, HanesBrands ... - Nasdaq
www.nasdaq.com - April 13 at 11:47 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Likely to Effect Ocera Therapeutics (OCRX) Stock Price
www.americanbankingnews.com - April 13 at 6:15 PM
streetinsider.com logoAfter-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...) - StreetInsider.com
www.streetinsider.com - April 13 at 8:04 AM
finance.yahoo.com logoOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in …
finance.yahoo.com - April 12 at 7:55 PM
finance.yahoo.com logoOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
finance.yahoo.com - April 12 at 7:55 PM
finance.yahoo.com logoETFs with exposure to Ocera Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:24 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - March 31 at 7:05 PM
finance.yahoo.com logoOcera to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 27 at 6:29 PM
americanbankingnews.com logoOcera Therapeutics Inc (OCRX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:03 PM
finance.yahoo.com logoOCERA THERAPEUTICS, INC. Financials
finance.yahoo.com - March 18 at 6:25 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 14 at 6:30 PM
finance.yahoo.com logoOcera Therapeutics, Inc.: Yet Another Step Towards Putting a New Drug Treatment for Chronic Orphan Liver Diseases
finance.yahoo.com - March 13 at 9:59 AM
nasdaq.com logoMid-Aternoon Market Update: Crude Oil Down 1.5%; Citi Trends Shares Rise On Earnings Beat
www.nasdaq.com - March 10 at 8:45 PM
finance.yahoo.com logoOcera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 10 at 9:19 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 10 at 9:19 AM
finanznachrichten.de logoGainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM...
www.finanznachrichten.de - March 9 at 11:51 PM
seekingalpha.com logoOcera Therapeutics (OCRX) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 6:50 PM
baystreet.ca logoCrushed in January, Shares of Ocera Therapeutics Bounce Back on Trial Data
www.baystreet.ca - March 9 at 12:47 AM
streetinsider.com logoOcera Therapeutics (OCRX) Says Data Confirms OCR-002 Lowered Ammonia, Correlated Statistically with Clinical Improvement in Patients with HE
www.streetinsider.com - March 8 at 7:45 PM
finance.yahoo.com logoOcera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
finance.yahoo.com - March 8 at 9:25 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - March 8 at 9:25 AM
finance.yahoo.com logoOcera to Present at the Cowen and Company 37th Annual Healthcare Conference
finance.yahoo.com - February 28 at 7:04 PM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera ...
www.businesswire.com - February 2 at 7:52 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.
finance.yahoo.com - February 2 at 7:52 PM
finance.yahoo.com logoOcera Therapeutics downgraded by JMP Securities
finance.yahoo.com - January 31 at 7:58 PM
streetinsider.com logoForm 8-K Ocera Therapeutics, Inc. For: Jan 30 - StreetInsider.com
www.streetinsider.com - January 31 at 8:01 AM

Social

Chart

Ocera Therapeutics (OCRX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff